{
    "title": "107_s186",
    "content": "The \"Generic Pharmaceutical Access and Choice for Consumers Act of 2001\" requires the use of generic drugs in various healthcare programs and sets therapeutic equivalence requirements for generic drugs. Sec. 201 of the \"Generic Pharmaceutical Access and Choice for Consumers Act of 2001\" establishes therapeutic equivalence standards for generic drugs. Congress finds that generic pharmaceuticals are approved by the FDA based on scientific testing, providing a safe and cost-effective alternative to brand-name drugs. The market has become more competitive due to the availability of generics, leading to significant cost savings estimated by the Congressional Budget Office. Generic pharmaceuticals cost between 25-60% less than brand-name drugs, saving an estimated $15-$30 per prescription. Independent studies show an average savings of $45.50 per prescription. The market share of generics has more than doubled in the last decade, from 19% to 43%. Each 1% increase in generic pharmaceutical use can save consumers an additional $1.32 billion annually. The Act aims to reduce prescription drug costs for the government and beneficiaries by promoting the use of generic drugs over brand-name ones, unless a therapeutically equivalent generic drug is not available or specifically requested by the prescribing provider or individual. The Act aims to reduce prescription drug costs by promoting the use of generic drugs over brand-name ones and increasing their utilization through FDA determinations of therapeutic equivalence. SEC. 247. USE OF GENERIC DRUGS REQUIRED under the Public Health Service Act. Each grant or contract under the Public Health Service Act for healthcare items must ensure that prescription drugs are filled with the generic form, unless specifically ordered by the provider or requested by the individual. The term 'generic form of the drug' refers to a drug approved under certain sections of the Federal Food, Drug, and Cosmetic Act. The Federal Food, Drug, and Cosmetic Act defines terms related to prescription drugs, including the nongeneric form of the drug and therapeutic equivalence. 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)) states that the amendment made by this section applies to any drug furnished on or after the date of enactment of this Act. SEC. 102. APPLICATION TO FEDERAL EMPLOYEES HEALTH BENEFITS PROGRAM. Section 8902 of title 5, United States Code, is amended to require carriers to provide, pay, or reimburse the cost of generic prescription drugs, unless the nongeneric form is specifically requested. This amendment applies to prescription drugs furnished during contract years beginning on or after January 1, 2002. SEC. 103. APPLICATION TO MEDICARE PROGRAM. Section 1861(t) of the Social Security Act is amended to define 'drugs' as the generic form unless no generic form is approved, or the nongeneric form is specifically requested. This amendment applies to prescription drugs furnished after the enactment of the Act. The amendment made by this section applies to prescription drugs furnished by Medicare+Choice plans starting on or after January 1, 2002. The amendment applies to prescription drugs provided by Medicare+Choice plans starting on or after January 1, 2002, including its application to the Medicaid program. The amendment to the Social Security Act requires states to use generic forms of drugs unless specifically requested by the provider or individual. This applies to prescription drugs provided by Medicare+Choice plans starting on or after January 1, 2002, including its application to the Medicaid program. The amendment made by this section applies to prescription drugs provided under State plans approved or renewed after the enactment of this Act. SEC. 225 of the Indian Health Care Improvement Act requires the use of generic drugs. SEC. 225 of the Indian Health Care Improvement Act mandates the use of generic drugs for prescription drug services provided by the Indian Health Service, unless a generic form is not available or specifically requested by the prescribing provider or individual. The amendment applies to drugs furnished after the enactment of the Act. The amendment mandates the use of generic drugs for prescription drug services provided by the Indian Health Service, unless specifically requested by the prescribing provider or individual. Chapter 17 of the title is amended to include a new item after section 1722A. Section 1722B of the Act requires the use of generic drugs. The amendments apply to prescription drugs provided after the enactment date. This section also applies to recipients of uniformed services health care. The Secretary of Defense must ensure that health care providers prescribe generic drugs unless a generic form is not approved or the nongeneric form is specifically requested. This requirement applies to prescription drugs provided after the enactment date and to recipients of uniformed services health care. The Secretary of Defense must ensure that health care providers prescribe generic drugs unless specifically requested by the individual for whom the drug is prescribed. A clerical amendment is made to the table of sections in the chapter. The amendments require the use of generic drugs, effective for drugs furnished after the enactment of the Act. It also applies to federal prisoners. The Attorney General must ensure that health care providers give federal prisoners generic drugs unless specifically ordered otherwise. The amendment made by this section applies to prescription drugs furnished on or after the date of enactment of this Act. Therapeutic equivalence requirements for generic drugs are outlined in Title II, specifically addressing the therapeutic equivalence of generic drugs. The FDA amended Section 505 of the Federal Food, Drug, and Cosmetic Act to determine the therapeutic equivalence of generic drugs to reference or listed drugs. The determination must be made before approval for new applications and confirmed for existing ones. The FDA amended Section 505 of the Federal Food, Drug, and Cosmetic Act to establish criteria for determining the therapeutic equivalence of generic drugs to reference or listed drugs. This includes ensuring that the generic drug has the same active ingredients, dosage form, route of administration, strength, and clinical effect as the reference drug. Additionally, the generic drug must not present any known bioequivalence issues or must meet appropriate bioequivalence standards. The FDA prohibits states from imposing additional requirements on drugs that have been determined to be therapeutically equivalent to reference or listed drugs. The Secretary will update the list of therapeutically equivalent drugs every 30 days. The amendments made by this section will take effect on the date of enactment of this Act. SENSE OF THE SENATE ON REQUIRING THE USE OF GENERIC PHARMACEUTICALS UNDER THE MEDICARE PROGRAM: The Senate believes legislation should mandate the safe and cost-effective use of generic drugs in conjunction with any comprehensive prescription drug benefit added to the Medicare program."
}